This document updates the recommendations on the management of Philadelphia
chromosome-negative myeloproliferative neoplasms (Ph-neg MPNs) published in 2011 by …

Janus tyrosine kinase (JAK) family of proteins have been identified as crucial proteins in
signal transduction initiated by a wide range of membrane receptors. Among the proteins in …

JAK inhibitors have been developed following the discovery of the JAK2V617F in 2005 as
the driver mutation of the majority of non-BCR-ABL1 myeloproliferative neoplasms (MPNs) …

Myelofibrosis: Clinicopathologic Features, Prognosis, and Management Page 1 Clinical
Advances in Hematology & Oncology Volume 16, Issue 2 February 2018 121 Myelofibrosis …

Janus kinase 2 (JAK2) signal transduction is a critical mediator of the immune response.
JAK2 is implicated in the onset of graft-versus-host disease (GVHD), which is a significant …

Background: Erlotinib (ELTN)-based targeted therapy as first-line treatment for epidermal
growth factor receptor (EGFR)-mutant lung cancers suffers from insufficient selectivity, side …

Abstract Background The Philadelphia chromosome-negative myeloproliferative neoplasms
(MPNs) are associated with increases in janus kinase 2 (JAK2) signaling, often resulting …

Myeloproliferative neoplasms (MPNs) include essential thrombocythemia, polycythemia
vera (PV), and primary myelofibrosis (MF). Phenotype-driver mutations of JAK2, CALR, and …

Low-dose thalidomide and prednisone alone or combined are effective therapies in some
persons with primary myelofibrosis (PMF) and anemia with or with RBC transfusion …

The introduction of JAK inhibitors, leading to regulatory approval of ruxolitinib, represents a
major therapeutic advance in myelofibrosis (MF). Most patients experience reduction in …